Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Changes in the sex ratio are a good indicator of changes in MS incidence - No

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Serum and cerebrospinal fluid neurofilament levels predict longitudinal atrophy of the cervical spinal cord in progressive MS

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Progressive effects of sildenafil on visual processing in rats

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Discrete finger sequences are widely represented in human striatum

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The influence of prolonged strength training upon muscle and fat in healthy and chronically diseased older adults

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Erythropoietin (EPO) is a part of an endogenous neuroprotective system in the brain and may address pathophysiological mechanisms in progressive multiple sclerosis (MS).

OBJECTIVE: To evaluate a treatment effect of EPO on progressive MS.

METHODS: This was a single-center, randomized, double-blind, placebo-controlled phase 2 trial, in which 52 patients with secondary or primary progressive MS were allocated to treatment with recombinant EPO (48,000 IU) or placebo, administered intravenously 17 times during 24 weeks. Patients had an Expanded Disability Status Score (EDSS) from 4 to 6.5 and clinical progression without relapses in the 2 preceding years. The primary outcome was the change in a composite measure of maximum gait distance, hand dexterity, and cognition from baseline to 24 weeks.

RESULTS: A total of 50 patients completed the study. Venesection was performed often but no thromboembolic events occurred. We found no difference in the primary outcome between the EPO and the placebo group using the intention-to-treat principle (p = 0.22). None of the secondary outcomes, neither clinical nor magnetic resonance imaging (MRI) measures showed any significant differences.

CONCLUSION: This study provides class II evidence that treatment with high-dose EPO is not an effective treatment in patients with moderately advanced progressive MS.

Original languageEnglish
JournalMultiple sclerosis
Volume23
Issue number5
Pages (from-to)675-685
ISSN1352-4585
DOIs
Publication statusPublished - 1 Apr 2017

ID: 48333647